Hydrogels: a promising therapeutic platform for inflammatory skin diseases treatment

Journal of Materials Chemistry B, Год журнала: 2024, Номер 12(33), С. 8007 - 8032

Опубликована: Янв. 1, 2024

Inflammatory skin diseases, such as psoriasis and atopic dermatitis, pose significant health challenges due to their long-lasting nature, potential for serious complications, risks, which requires treatments that are both effective exhibit minimal side effects. Hydrogels offer an innovative solution biocompatibility, tunability, controlled drug delivery capabilities, enhanced treatment adherence minimized effects risk. This review explores the mechanisms guide design of hydrogel therapeutic platforms from multiple perspectives, focusing on components hydrogels, adjustable physical chemical properties, interactions with cells drugs underscore clinical potential. We also examine various agents dermatitis can be integrated into including traditional drugs, novel compounds targeting oxidative stress, small molecule biologics, emerging therapies, offering insights advantages. Additionally, we trial data evaluate effectiveness safety hydrogel-based in managing under complex disease conditions. Lastly, discuss current future opportunities therapeutics treating improving barrier penetration developing multifunctional highlight enhance long-term stability.

Язык: Английский

---

RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing

Frontiers in Immunology, Год журнала: 2020, Номер 11

Опубликована: Ноя. 23, 2020

Keloids are disfiguring, fibroproliferative growths and their pathogenesis remains unclear, inhibiting therapeutic development. Available treatment options have limited efficacy harbor safety concerns. Thus, there is a great need to clarify keloid pathomechanisms that may lead novel treatments. In this study, we aimed elucidate the profile of lesional non-lesional skin compared normal skin. We performed gene (RNAseq, qRT-PCR) protein (immunohistochemistry) expression analyses on biopsy specimens obtained from African American (AA) patients healthy AA controls. Fold-change≥2 false-discovery rate (FDR)<0.05 was used define significance. found versus showed significant up-regulation markers T-cell activation/migration (ICOS, CCR7), Th2- (IL-4R, CCL11, TNFSF4/OX40L), Th1- (CXCL9/CXCL10/CXCL11), Th17/Th22- (CCL20, S100As) pathways, JAK/STAT-signaling (JAK3) (false-discovery [FDR]<0.05). Non-lesional also exhibited similar trends. observed increased cellular infiltrates in tissues, including T-cells, dendritic cells, mast as well greater IL-4rα + , CCR9 periostin immunostaining. sum, comprehensive molecular profiling demonstrated both show immune alternations, particularly Th2 JAK3 expression. This advocates for investigation treatments targeting axis and/or patients.

Язык: Английский

---

Management of atopic dermatitis: a narrative review

The Medical Journal of Australia, Год журнала: 2022, Номер 216(11), С. 587 - 593

Опубликована: Май 29, 2022

Atopic dermatitis (atopic eczema) is the most common inflammatory skin disease and has a significant burden on quality of life patients, families caregivers. Its pathogenesis complex interplay between genetics environment, involving impaired barrier function, immune dysregulation primarily Th2 pathway, itch, microbiome. Restoration integrity with regular emollients prompt topical anti-inflammatory therapies are mainstays treatment. Systemic therapy considered for moderate to severe disease. New understanding pathways developments in targeted systemic immunotherapies have significantly advanced atopic management. Dupilumab safe effective treatment that now available Australia. Other promising agents include Janus kinase, interleukin (IL)-13 IL-31 inhibitors.

Язык: Английский

---

Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis ( ADVISE )

Journal of the European Academy of Dermatology and Venereology, Год журнала: 2023, Номер 37(7), С. 1366 - 1374

Опубликована: Янв. 25, 2023

Etrasimod is an oral, selective, sphingosine 1-phosphate (S1P) receptor1,4,5 modulator in development for immune-mediated inflammatory disorders. Efficacy and safety of orally administered S1P receptor modulation atopic dermatitis (AD) have not yet been examined.To assess the efficacy etrasimod monotherapy adults with moderate-to-severe AD.In this phase 2, randomized, double-blind, placebo-controlled trial, participants (≥18 years) AD defined as baseline validated Investigator's Global Assessment (vIGA-AD) score ≥ 3, Eczema Area Severity Index (EASI) 16, body surface area involvement ≥10% were randomized 1:1:1 to once-daily oral 1 mg, 2 mg or placebo 12 weeks. The primary outcome was percent change EASI from at week 12, assessed Full Analysis Set (all participants). Key secondary outcomes achievement a vIGA-AD 0 ≥2-point improvement EASI-75 response Week 12. Safety during double-blind period.One hundred forty (n = 47), 47) 46). At -57.2% 2-mg group versus -48.4% (p 0.18). A significantly greater proportion receiving achieved scores (29.8% vs. 13.0%; p 0.045); however, statistically significant placebo. Treatment-emergent adverse events (AEs) occurred 59.6%, 40.4% 47.8% placebo, respectively. There no serious AEs deaths.The met, although observed on several clinician- patient-assessed measures, both 1- doses well tolerated, warranting further clinical investigation AD.

Язык: Английский

---

Efficacy of biologics in atopic dermatitis

Expert Opinion on Biological Therapy, Год журнала: 2020, Номер 20(5), С. 525 - 538

Опубликована: Янв. 31, 2020

Introduction: Atopic dermatitis (AD) is a heterogeneous disease. Recent advancements in understanding AD pathogenesis resulted the exponential expansion of its therapeutic pipeline, particularly following success and FDA-approval dupilumab. Different phenotypes by age ethnicity have also recently been described clinical studies emerging treatments will further clarify role each cytokine pathway AD.Areas covered: We review impressive repertoire biologics for treatment moderate-to-severe AD, including those targeting Th2, Th22, Th17/IL-23 IgE. highlight scientific rationale behind approach provide discussion most recent efficacy safety data.Expert opinion: complex disease research has identified numerous endotypes, reinforcing developing targeted therapeutics to antagonize these factors. Dupilumab revolutionized mechanistic offer crucial insight into pathogenesis. Nevertheless, this biologic does not work everyone, highlighting need more precise address unique immune fingerprints subset. Ultimately complement our molecular map help push management an era personalized medicine.

Язык: Английский

---